To print: Select File and then Print from your browser's menu

Title: Anti-p53 Antibodies And C-Reactive Protein Are Prognostic Factors In Recurrent Oesophageal Cancer

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12563234&dopt=Abstract

Surgery 2003;133:1:24-31. "Treatment response and prognosis of patients after recurrence of esophageal cancer."
02/07/2003 01:59:13 PM
By James Adams

Serum concentrations of anti-p53 antibodies and C-reactive protein appear to be independent prognostic factors in patients with recurrent oesophageal cancer. Investigators, from the Department of Academic Surgery and Radiology at Chiba University Graduate School of Medicine in Chiba, Japan, studied 258 patients who underwent radical oesophagectomy with extended lymphadenectomy for oesophageal squamous cell carcinoma between 1990 and 1999. Operative specimens were analyzed and depth of tumour invasion and lymph node metastases were also evaluated. To monitor recurrence, tumour markers were assessed every three months, ultrasound examinations were performed every six months and computed tomography was performed annually. Mean follow-up after surgery was 22 months. Ninety-five out of 258 patients experienced recurrence. Seventy-six of these patients received non-surgical treatment and seven underwent operative intervention. The remaining twelve received no treatment. Clinicopathologic features of the recurrent tumours were analyzed, and concentrations of serum anti-p53 antibody, serum C-reactive protein and albumin were determined. Thirty-four percent of the patients who were treated non-surgically responded to treatment. Response was associated with type of recurrence, history of perioperative adjuvant therapy, time of recurrence, number of recurrent tumours, albumin concentration, serum anti-p53 antibody concentration and serum C-reactive protein concentration. Multivariate analysis revealed that serum anti-p53 antibody concentration and serum C-reactive protein concentration independently predicted treatment response.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12563234&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.